Delivering unplanned RT (mainly with palliative/symptomatic aims) in advanced breast cancer patients on Cyclin-D1/CDK4 and CDK6 inhibitors in prospective trials has produced empirically based treatment not supported by an appropriate rationale and consolidated approach, e g., in terms of RT intent, dose, and scheduling. Here, CDK6 is linked to breast carcinoma.